Tetrandrine stabilizes NCOA4 to promote ferritinophagy-mediated ferroptosis and enhance antitumor immunity in NSCLC
Authors:
Open Access
- 22 October 2026
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
Abstract
Background: Natural products are an important source of anticancer agents. Tetrandrine is a natural bisbenzylisoquinoline alkaloid, but how it regulates ferritinophagy and ferroptosis in non-small cell lung cancer (NSCLC) and affects antitumor immunity remains unclear. This study investigated its mechanism of action and potential for combination with anti-PD-1 therapy. Methods: Antitumor activity was evaluated in NSCLC cell lines, patient-derived lung adenocarcinoma organoids, and mouse tumor models. Proteomic and transcriptomic analyses, pharmacological interventions, and gene overexpression and knockdown experiments were used to investigate ferritinophagy and ferroptosis. Target-binding, protein stability, and ubiquitination assays examined the regulation of nuclear receptor coactivator 4 (NCOA4). Co-immunoprecipitation, proximity ligation assays, structural prediction, and truncation and deletion analyses characterized the NCOA4–TAX1BP1 interaction. Tumor cell–PBMC co-cultures and LLC and CMT167 syngeneic tumor models were used to assess T-cell responses and combination treatment. Results: Tetrandrine reduced NSCLC cell and organoid viability and increased intracellular Fe²⁺ accumulation and lipid peroxidation. Ferroptosis inhibitors partially attenuated these effects. Tetrandrine promoted lysosomal ferritin degradation and directly bound NCOA4, increasing its stability. HERC2 downregulation and reduced K48-linked NCOA4 ubiquitination contributed to this stabilization. Tetrandrine also enhanced the NCOA4–TAX1BP1 interaction. Deletion of NCOA4 residues 540–560 weakened this interaction and attenuated tetrandrine-induced iron accumulation, lipid peroxidation, and growth inhibition. In co-culture and animal models, tetrandrine increased markers of CD8⁺ T-cell activation or effector function, with some effects attenuated by iron chelation. Combined tetrandrine and anti-PD-1 treatment produced greater tumor suppression than either monotherapy in both syngeneic models. Conclusions: Tetrandrine stabilizes NCOA4 and enhances its interaction with TAX1BP1, promoting ferritinophagy and subsequent ferroptosis. Its antitumor activity is accompanied by enhanced CD8⁺ T-cell effector responses in the tumor microenvironment and improved efficacy of anti-PD-1 treatment, supporting further investigation of tetrandrine for NSCLC therapy.Keywords
Funding Information
- National Natural Science Foundation of China (82405114)
- National Natural Science Foundation of China (82272863)
- China Postdoctoral Science Foundation (2022M721411)
- Graduate Student Scientific Research and Practice Innovation Projects in Jiangsu Province (SJCX24_0752)
- Suzhou "Science, Education and Health Strengthening" Project (ZDXM2025025)
- Nanjing Medical University-Qilu Clinical Research Fund Project (2024KF0241)
- Yishan Research Project of Jiangsu Cancer Hospital (YSZD202405)